A Phase 1/2 Study of the Highly Selective EGFR Inhibitor BLU-701 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Brief description of study

The purpose of the study is to determine the overall safety of the study drug BLU-701, as assessed by the type, frequency, severity, timing, and relationship to study drug of adverse events (AEs), and changes in vital signs, electrocardiograms, and safety laboratory tests. We want to find the maximum tolerated dose and recommended Phase 2 dose.

The study drug BLU-701 is investigational, which means that the study drug has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test the study drug in the current trial.

Clinical Study Identifier: s21-01149
ClinicalTrials.gov Identifier: NCT05153408

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.